Introduction
Latent tuberculosis infection, often abbreviated as LTBI, is identified differently from active tuberculosis disease because it does not usually cause obvious illness and cannot be confirmed by symptoms alone. In this condition, a person has been infected with Mycobacterium tuberculosis, but the immune system has contained the bacteria so they remain alive in the body without causing clinical disease. For that reason, diagnosis depends mainly on evidence of immune sensitization to the bacterium, combined with careful exclusion of active tuberculosis.
Accurate diagnosis matters because latent infection is not harmless. Although the person may feel well, the bacteria can later reactivate and cause infectious pulmonary or extrapulmonary disease, especially if the immune system weakens. Identifying latent infection allows clinicians to consider preventive treatment and reduce the risk of future tuberculosis. The diagnostic process therefore focuses on two linked questions: has the person been infected, and is there any evidence that the infection has already become active disease?
Recognizing Possible Signs of the Condition
Latent tuberculosis infection usually produces no symptoms. This is the central clinical feature that distinguishes it from active tuberculosis. Many people are discovered only because they were screened after exposure to someone with contagious tuberculosis, before starting certain medications that suppress immunity, or during routine health assessments in higher-risk settings.
Because LTBI itself is asymptomatic, the “signs” that raise suspicion are often indirect. A recent close contact with a person who has active tuberculosis is one of the strongest clues. Other situations that prompt evaluation include birth or long-term residence in a country where tuberculosis is common, work in healthcare, incarceration, homelessness, or residence in congregate settings where transmission risk is higher. Clinicians also consider latent infection in people with HIV, diabetes, chronic kidney disease, silicosis, or planned organ transplantation, because these conditions increase the risk of reactivation.
If a person has cough, fever, night sweats, weight loss, chest pain, or coughing up blood, that is not typical of latent infection and suggests active tuberculosis or another illness. In practice, such symptoms shift the evaluation away from LTBI alone and toward a full workup for active disease.
Medical History and Physical Examination
The diagnostic process begins with a detailed medical history. Healthcare professionals ask about known exposure to tuberculosis, prior positive testing, previous treatment for latent or active TB, travel or residence in high-prevalence regions, occupation, living conditions, and immunosuppressive therapies such as corticosteroids, biologic agents, or chemotherapy. They also review conditions that weaken cell-mediated immunity, since the immune response to tuberculosis is central to both diagnosis and disease control.
History-taking also helps determine whether the person could have active tuberculosis instead of latent infection. Clinicians ask specifically about respiratory symptoms, constitutional symptoms, and any signs of extrapulmonary involvement such as swollen lymph nodes, back pain, urinary symptoms, or neurologic complaints. Previous chest imaging, prior tuberculin skin tests, and past interferon-gamma release assay results are reviewed when available.
The physical examination in LTBI is often normal, which is expected. Even so, it remains important because abnormal findings may point to active disease or another diagnosis. The clinician may examine the lungs, check for fever, weight loss, lymph node enlargement, and assess general health status. The presence of abnormal respiratory findings, cachexia, or focal signs of disease would make latent infection less likely and prompt further evaluation.
Diagnostic Tests Used for Latent tuberculosis infection
There is no single test that directly proves latent tuberculosis infection in the way a blood culture might prove bacteremia. Instead, diagnosis relies on tests that detect the immune system’s memory of tuberculosis exposure. The two main tests are the tuberculin skin test (TST) and the interferon-gamma release assay (IGRA). Both measure immune sensitization rather than bacterial activity itself.
The tuberculin skin test involves injecting a small amount of purified protein derivative under the skin, usually on the forearm. If the immune system has previously encountered tuberculosis antigens, a delayed hypersensitivity reaction develops over 48 to 72 hours. The resulting area of induration, not redness alone, is measured in millimeters. The size threshold for a positive test depends on the patient’s risk factors and likelihood of progression to disease. This test is inexpensive and widely used, but it can be falsely positive in people who received Bacille Calmette-Guérin (BCG) vaccination or were exposed to certain non-tuberculous mycobacteria. It can also be falsely negative in people with very recent infection, severe immunosuppression, or poor immune responsiveness.
Interferon-gamma release assays are blood tests that measure release of interferon-gamma from sensitized T cells after they are exposed to tuberculosis-specific antigens. Unlike the skin test, IGRAs are not affected by prior BCG vaccination, which makes them especially useful in vaccinated populations. Common assays include QuantiFERON and T-SPOT.TB. These tests are generally more specific than the skin test, but they still cannot distinguish latent infection from active tuberculosis. They also may be less reliable in very young children or in severe immunosuppression, where immune responses can be blunted.
Imaging is not used to diagnose latent infection directly, but it is essential to exclude active pulmonary disease. A chest radiograph is the standard imaging test. In a person with LTBI, the chest X-ray is usually normal. Findings such as cavitation, infiltrates, pleural effusion, or miliary patterns suggest active or previously healed tuberculosis and require further assessment. If the radiograph is abnormal or symptoms strongly suggest disease, a chest computed tomography scan may be ordered for better definition of lung and lymph node involvement.
Microbiologic tests are not usually positive in pure latent infection because there is no active bacterial shedding. However, if there is any suspicion of active disease, sputum testing becomes important. Sputum smears, nucleic acid amplification tests, and cultures can detect organisms from the respiratory tract. A negative sputum result does not confirm LTBI by itself, but the absence of microbiologic evidence, together with normal imaging and lack of symptoms, supports latent rather than active disease.
Functional tests are not specific for tuberculosis itself, but they may be used to evaluate the consequences of suspected active disease or to assess whether symptoms from another cause are present. For example, pulmonary function testing may be considered if another lung disorder is suspected. These tests do not establish LTBI, but they can help clinicians interpret respiratory complaints that might otherwise be incorrectly attributed to tuberculosis.
Tissue examination is reserved for situations in which localized disease is suspected. If enlarged lymph nodes, pleural abnormalities, bone lesions, or other focal findings are present, clinicians may obtain a biopsy. Histologic examination may show granulomatous inflammation, and special stains or cultures can identify mycobacteria. In true latent infection, tissue sampling is usually not necessary because there is no active lesion to biopsy. When tissue is taken, it is typically because clinicians are trying to rule out active extrapulmonary tuberculosis or another diagnosis.
Interpreting Diagnostic Results
Interpretation of LTBI testing requires combining the test result with clinical context. A positive TST or IGRA indicates infection with tuberculosis organisms at some point in the past or present, but it does not tell doctors whether the infection is latent or active. Therefore, a positive immune-based test must be followed by evaluation for symptoms and chest imaging, and sometimes microbiologic testing, to exclude active disease.
If the patient has no symptoms, has a normal chest radiograph, and no evidence of active extrapulmonary disease, a positive TST or IGRA is typically interpreted as latent tuberculosis infection. In that setting, the immune system appears to have contained the organism, but viable bacteria may still be present in a dormant state. If symptoms or imaging abnormalities are present, the same positive result may instead support active tuberculosis, and additional testing is required before latent infection can be diagnosed.
Negative tests do not always rule out LTBI. A person who was infected very recently may not yet have developed a detectable immune response. Immunosuppression, advanced age, severe illness, and some chronic conditions can also lead to false-negative results. When the risk of exposure or progression is high, clinicians may repeat testing after the window period or interpret a negative result cautiously rather than exclude infection outright.
Results must also be interpreted differently in people with known BCG vaccination. A positive TST may reflect prior vaccination rather than true infection, particularly if the reaction is small and the person’s epidemiologic risk is low. In such cases, IGRA is often preferred because it is more specific for M. tuberculosis. On the other hand, in some patients with very high pretest probability, clinicians may consider even a borderline or discordant result significant enough to justify preventive treatment.
Conditions That May Need to Be Distinguished
The main diagnostic challenge is distinguishing latent infection from active tuberculosis. Active disease may present with the same immunologic test results as latent infection, so symptoms, imaging, and microbiologic studies are needed to separate the two. A person with fever, persistent cough, weight loss, night sweats, or radiographic abnormalities should not be labeled as having LTBI until active disease is excluded.
Other conditions can also mimic aspects of the evaluation. Non-tuberculous mycobacterial exposure can occasionally interfere with skin testing. Prior BCG vaccination can cause a false-positive TST. Sarcoidosis, fungal infections, malignancy, and other causes of granulomatous disease may produce imaging or tissue findings that resemble tuberculosis, especially when extrapulmonary involvement is suspected. Chronic lung diseases may also cause cough or abnormal X-ray findings that prompt a tuberculosis workup even when infection is absent.
Clinicians differentiate these conditions by integrating exposure history, immune testing, imaging patterns, microbiologic results, and, when needed, pathology. The goal is not only to identify infection but to avoid missing active tuberculosis, since that would require urgent treatment and has public health implications.
Factors That Influence Diagnosis
Several patient-specific factors affect how LTBI is diagnosed. Age matters because very young children may have weaker or less predictable responses to immune-based tests, and older adults may have declining immune responses as well. Immunosuppression from HIV, transplant medications, biologic therapies, or steroids can reduce test sensitivity and complicate interpretation.
Exposure intensity also affects diagnostic strategy. A person with a recent close household contact may be tested even if the first test is negative, because immune conversion can take weeks. In high-risk settings, repeat testing may be recommended after the initial exposure window. The likelihood of prior tuberculosis infection also matters: in a person from a high-burden country, a positive test is more likely to reflect true infection than in someone with no epidemiologic risk.
Pregnancy, kidney disease, diabetes, and other chronic illnesses do not change the definition of LTBI, but they can influence which tests are preferred and how aggressively results are pursued. In some settings, IGRAs are favored because they require only one patient visit and avoid reading-dependent variability. In others, the skin test remains practical and accessible. Local prevalence and resource availability therefore play a role in the diagnostic pathway.
Conclusion
Latent tuberculosis infection is diagnosed by combining exposure assessment, symptom review, physical examination, and immune-based testing, with chest imaging used to exclude active disease. Because LTBI usually causes no symptoms and does not produce positive cultures in routine practice, diagnosis depends on recognizing prior sensitization to Mycobacterium tuberculosis through a tuberculin skin test or interferon-gamma release assay. A normal clinical assessment and normal chest radiograph support latent infection, while symptoms, abnormal imaging, or positive microbiology point toward active tuberculosis instead.
In practice, the diagnosis is an exercise in medical reasoning rather than a single definitive test. Doctors interpret results in light of exposure history, immune status, age, and the likelihood of progression to disease. This combined approach allows them to identify latent infection accurately, avoid misclassifying active tuberculosis, and decide whether preventive treatment is appropriate.